Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Cipla
Pharma
Sun-Organon, Astellas, BeOne—Fierce Pharma Asia
Sun will buy Organon for $11.75 billion. Astellas projects Xtandi sales declines in FY2026. BeOne has eyes on a PD-1xCTLA-4xVEGF trispecific antibody.
Angus Liu
May 1, 2026 8:43am
Gilead inks Biktarvy settlements with 3 generic drug makers
Oct 7, 2025 7:40am
RemeGen, Roche, Hengrui and more—Fierce Pharma Asia
May 16, 2025 10:20am
FDA slams 3 Indian drugmakers in flurry of recent Form 483s
Apr 16, 2024 8:45am
Big Pharma CEOs in China, AstraZeneca, WuXi—Fierce Pharma Asia
Mar 29, 2024 10:10am
Sanofi calls on 3 drugmakers to market its meds overseas
Mar 27, 2024 9:57am
